Blast From The Past:
I am old enough to remember the “big four” biotech giants that dominated the landscape. Of course CELG is no longer with us, as BMY is acquiring the name. BIIB has been acting well, with monster weekly gains of 31 and 26% weeks ending 10/25/19 and 2/7, although it is now 19% off most recent 52 week highs (gains of hope for Alzheimer’s, and check chart of CGEN doing well in space too). AMGN is 16% off its own most recent yearly peak, and is defending the very round 200 number at the moment. That leaves us with GILD, which just two sessions ago was at 2 year highs. Investors are showing belief in a coronavirus development, but to be honest this name was the one with the “dead money” moniker attached to it for a couple years. Is this a sleeping giant among the remaining three? On a YTD basis it has the momentum up 10%, as BIIB is higher by 2%, and AMGN is lower by 15%. It also has the best dividend yield at 3.8%.